Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Zymeworks BC Inc. (ZYME) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/21/2022 8-K Quarterly results
10/19/2022 8-K Quarterly results
10/18/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Notice of Alteration",
"Notice of Articles"
10/12/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Notice of Delisting or Failure to...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
10/04/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Zymeworks Reminds Shareholders to Vote FOR its Redomicile"
10/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day"
09/26/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile"
09/22/2022 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/16/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile"
09/12/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin at European Society for Medical Oncology Annual Congress"
09/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware"
09/06/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Zymeworks Announces Release of ESMO Abstract for Phase 1study of Zanidatamab Zovodotin in Solid Cancers"
09/02/2022 8-K Other Events  Interactive Data
Docs: "FORM 8-K"
08/26/2022 8-K Unregistered Sales of Equity Securities  Interactive Data
08/19/2022 8-K Quarterly results
08/12/2022 8-K Other Events  Interactive Data
08/05/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results"
08/01/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "FORM 8-K",
"Zymeworks Announces Participation in Upcoming Investor Conferences"
07/25/2022 8-K Quarterly results
07/22/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
07/15/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/27/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
05/02/2022 8-K/A Quarterly results
05/02/2022 8-K Quarterly results
04/29/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons Vancouver, Canada and Seattle, Washington - Zymeworks Inc. , a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today confirmed it has received an unsolicited, non-binding proposal from All Blue Falcons FZE and its affiliates to purchase the Company for $10.50 per share in cash. The Zymeworks board of directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all Zymeworks shareholders. The board reminds shareholders that no formal offer has been made by ABF, and as such there is no need for Zymeworks shareholders to take any action at this time. If a formal offer is made, it..."
04/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer"
04/27/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology Annual Meeting"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy